A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced gastrointestinal stromal tumor (GIST).
Ping Chi(Memorial Sloan Kettering Cancer Center), William D. Tap(Memorial Sloan Kettering Cancer Center), Gary A. Ulaner(Memorial Sloan Kettering Cancer Center), Aimeé M. Crago(Memorial Sloan Kettering Cancer Center), Sinchun Hwang(Memorial Sloan Kettering Cancer Center), Sam S. Yoon(Columbia University Irving Medical Center), Moriah Martindale(Memorial Sloan Kettering Cancer Center), Mrinal M. Gounder(Memorial Sloan Kettering Cancer Center), Mark A. Dickson(Memorial Sloan Kettering Cancer Center), Benjamin A. Nacev(University of Pittsburgh), Mercedes M. Condy(Roche (Switzerland)), Sujana Movva(Memorial Sloan Kettering Cancer Center), Haley T. Phelan(Memorial Sloan Kettering Cancer Center), Mary Louise Keohan(Roche (Switzerland)), Samuel Singer(Memorial Sloan Kettering Cancer Center), Ciara M. Kelly(Memorial Sloan Kettering Cancer Center), Cristina R. Antonescu(Memorial Sloan Kettering Cancer Center), Matthew D. Biniakewitz(Memorial Sloan Kettering Cancer Center), Sandra P. D’Angelo(Memorial Sloan Kettering Cancer Center), Li‐Xuan Qin(Memorial Sloan Kettering Cancer Center)
Cited by 21
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k